Literature DB >> 35285963

Continued Risk of Dietary Supplements Adulterated With Approved and Unapproved Drugs: Assessment of the US Food and Drug Administration's Tainted Supplements Database 2007 Through 2021.

C Michael White1.   

Abstract

The US Food and Drug Administration created the Tainted Dietary Supplement Database in 2007 to identify dietary supplements adulterated with active pharmaceutical ingredients (APIs). This article compares the determination of API adulteration in dietary supplements from the 10-year time period of 2007 through 2016 to the most recent 5-year period of 2017 through 2021. From 2007 through 2021, 1068 unique products were found to be adulterated with APIs. Sexual enhancement and weight loss dietary supplements are the most common products adulterated with APIs. Phosphodiesterase-5 inhibitors are commonly included in sexual enhancement dietary supplements and a single product can include up to 5 APIs. Sibutramine, a drug removed from the market due to cardiovascular adverse events, is the most included adulterant API in weight loss products, although sibutramine analogues, phenolphthalein (which was removed from the US market because of cancer risk), and fluoxetine were also included. While muscle-building dietary supplements were commonly adulterated before 2016, since 2017 no additional adulterated products have been identified. The lack of disclosure of APIs in dietary supplements, circumventing the normal procedure with clinician oversight of prescription drug use, and the use of APIs that are banned by the Food and Drug Administration or used in combinations that were never studied are important health risks for consumers.
© 2022, The American College of Clinical Pharmacology.

Entities:  

Keywords:  Food and Drug Administration; adulteration; clinical pharmacology (CPH); dietary supplement safety; drug-food interactions

Mesh:

Substances:

Year:  2022        PMID: 35285963     DOI: 10.1002/jcph.2046

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   2.860


  4 in total

1.  First-Time Submassive Pulmonary Embolism Likely Caused by Testosterone-Enhancing Supplement.

Authors:  Hazem Alakhras; Brent R Yelton; Hamza Beano
Journal:  Cureus       Date:  2022-05-18

2.  Dietary Supplements Questioned in the Polish Notification Procedure upon the Basis of Data from the National Register of Functional Foods and the European System of the RASFF.

Authors:  Kacper Wróbel; Anna Justyna Milewska; Michał Marczak; Remigiusz Kozłowski
Journal:  Int J Environ Res Public Health       Date:  2022-07-03       Impact factor: 4.614

3.  Healthcare Professionals' Knowledge and Behaviors Regarding Drug-Dietary Supplement and Drug-Herbal Product Interactions.

Authors:  Zorica Stanojević-Ristić; Isidora Mrkić; Aleksandar Ćorac; Mirjana Dejanović; Radoslav Mitić; Leonida Vitković; Julijana Rašić; Dragana Valjarević; Aleksandar Valjarević
Journal:  Int J Environ Res Public Health       Date:  2022-04-03       Impact factor: 3.390

4.  Analysis of Select Dietary Supplement Products Marketed to Support or Boost the Immune System.

Authors:  Cindy Crawford; Bharathi Avula; Andrea T Lindsey; Abraham Walter; Kumar Katragunta; Ikhlas A Khan; Patricia A Deuster
Journal:  JAMA Netw Open       Date:  2022-08-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.